Literature DB >> 8454352

Complement component C5 modulates the systemic tumor necrosis factor response in murine endotoxic shock.

P A Barton1, J S Warren.   

Abstract

Patients with disseminated Neisseria meningitidis infections (meningococcemia) suffer from a fulminant shock syndrome that is accompanied by extraordinarily high concentrations in serum of tumor necrosis factor (TNF). People with homozygous deficiencies of late complement components (C5, C6, C7, and C8) experience a high incidence of disseminated neisserial infections yet suffer from an attenuated form of the disease. The mechanisms that account for this disparity in host response are unclear, but they may in part be related to differences in the systemic TNF response that are modulated by terminal complement components (C5 to C9). The role of C5 in the modulation of the systemic endotoxin-induced TNF response was studied with matched strains of C5-deficient (B10 D2/Osn) and complement-sufficient (B10 D2/Nsn) mice. Following lipopolysaccharide (LPS) administration, complement-sufficient mice exhibited more rapid increases in pulmonary and hepatic vascular permeabilities than did C5-deficient controls. Complement-sufficient mice developed acute passive hepatic congestion, they appeared more ill than C5-deficient mice, and they exhibited a twofold greater rise in serum TNF activity compared with that by C5-deficient mice. C5-deficient mice reconstituted with normal serum before an LPS injection exhibited pulmonary and hepatic vascular permeability increases and serum TNF levels approaching those observed in complement-sufficient mice. Alveolar and peritoneal macrophages isolated from complement-sufficient and C5-deficient mice and incubated in heat-inactivated serum did not exhibit differences in TNF mRNA expression or secreted TNF activity following stimulation with LPS. However, incubation of macrophages in complement-sufficient mouse serum (before LPS stimulation) resulted in increased TNF mRNA expression and TNF activity compared with those in cells incubated in C5-deficient serum. In vitro studies employing human complement components and peripheral blood monocytes revealed that recombinant C5a, in the presence or absence of LPS, can induce increased concentrations of TNF and that C5b to C9 had no additional modulatory effect on the TNF response. These data suggest that C5 modulates the endotoxin-triggered TNF response. The role of complement components distal to C5 (i.e., C5b to C9) in the endotoxin-triggered TNF response remains unclear.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8454352      PMCID: PMC281388          DOI: 10.1128/iai.61.4.1474-1481.1993

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  44 in total

1.  Identification of an inducible endothelial-leukocyte adhesion molecule.

Authors:  M P Bevilacqua; J S Pober; D L Mendrick; R S Cotran; M A Gimbrone
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

2.  Rapid purification of human peripheral blood monocytes by centrifugation through Ficoll-Hypaque and Sepracell-MN.

Authors:  M C Vissers; S A Jester; J C Fantone
Journal:  J Immunol Methods       Date:  1988-06-13       Impact factor: 2.303

3.  Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia.

Authors:  K J Tracey; Y Fong; D G Hesse; K R Manogue; A T Lee; G C Kuo; S F Lowry; A Cerami
Journal:  Nature       Date:  1987 Dec 17-23       Impact factor: 49.962

4.  Comparative O2-. responses of lung macrophages and blood phagocytic cells in the rat. Possible relevance to IgA immune complex induced lung injury.

Authors:  J S Warren; R G Kunkel; K J Johnson; P A Ward
Journal:  Lab Invest       Date:  1987-09       Impact factor: 5.662

5.  Synthesis and release of platelet-activating factor by human vascular endothelial cells treated with tumor necrosis factor or interleukin 1 alpha.

Authors:  F Bussolino; G Camussi; C Baglioni
Journal:  J Biol Chem       Date:  1988-08-25       Impact factor: 5.157

6.  Acute in vivo effects of human recombinant tumor necrosis factor.

Authors:  D G Remick; R G Kunkel; J W Larrick; S L Kunkel
Journal:  Lab Invest       Date:  1987-06       Impact factor: 5.662

7.  Recombinant tumor necrosis factor increases pulmonary vascular permeability independent of neutrophils.

Authors:  C J Horvath; T J Ferro; G Jesmok; A B Malik
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

8.  Endothelial cell gene expression of a neutrophil chemotactic factor by TNF-alpha, LPS, and IL-1 beta.

Authors:  R M Strieter; S L Kunkel; H J Showell; D G Remick; S H Phan; P A Ward; R M Marks
Journal:  Science       Date:  1989-03-17       Impact factor: 47.728

Review 9.  Cachectin/tumor necrosis factor exerts endocrine, paracrine, and autocrine control of inflammatory responses.

Authors:  B Sherry; A Cerami
Journal:  J Cell Biol       Date:  1988-10       Impact factor: 10.539

10.  C5a stimulates secretion of tumor necrosis factor from human mononuclear cells in vitro. Comparison with secretion of interleukin 1 beta and interleukin 1 alpha.

Authors:  S Okusawa; K B Yancey; J W van der Meer; S Endres; G Lonnemann; K Hefter; M M Frank; J F Burke; C A Dinarello; J A Gelfand
Journal:  J Exp Med       Date:  1988-07-01       Impact factor: 14.307

View more
  13 in total

Review 1.  C1 inhibitor: biologic activities that are independent of protease inhibition.

Authors:  Alvin E Davis; Shenghe Cai; Dongxu Liu
Journal:  Immunobiology       Date:  2006-12-11       Impact factor: 3.144

Review 2.  Biological activities of C1 inhibitor.

Authors:  Alvin E Davis; Pedro Mejia; Fengxin Lu
Journal:  Mol Immunol       Date:  2008-07-31       Impact factor: 4.407

3.  Circulating complement proteins in patients with sepsis or systemic inflammatory response syndrome.

Authors:  S Stöve; T Welte; T O Wagner; A Kola; A Klos; W Bautsch; J Köhl
Journal:  Clin Diagn Lab Immunol       Date:  1996-03

Review 4.  Role of C3, C5 and anaphylatoxin receptors in acute lung injury and in sepsis.

Authors:  Markus Bosmann; Peter A Ward
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

Review 5.  Animal models of inherited complement deficiency.

Authors:  S Linton
Journal:  Mol Biotechnol       Date:  2001-06       Impact factor: 2.695

6.  Cytokine-induced neutrophil chemoattractant in a rat model of lipopolysaccharide-induced acute lung injury.

Authors:  H Yamasawa; Y Ishii; S Kitamura
Journal:  Inflammation       Date:  1999-06       Impact factor: 4.092

7.  Mechanisms of enhanced lung injury during sepsis.

Authors:  B J Czermak; M Breckwoldt; Z B Ravage; M Huber-Lang; H Schmal; N M Bless; H P Friedl; P A Ward
Journal:  Am J Pathol       Date:  1999-04       Impact factor: 4.307

8.  Acute lung injury induced by lipopolysaccharide is independent of complement activation.

Authors:  Daniel Rittirsch; Michael A Flierl; Danielle E Day; Brian A Nadeau; Stephanie R McGuire; Laszlo M Hoesel; Kyros Ipaktchi; Firas S Zetoune; J Vidya Sarma; Lin Leng; Markus S Huber-Lang; Thomas A Neff; Richard Bucala; Peter A Ward
Journal:  J Immunol       Date:  2008-06-01       Impact factor: 5.422

9.  Serum-induced potentiation of tumor necrosis factor alpha production by human monocytes in response to staphylococcal peptidoglycan: involvement of different serum factors.

Authors:  E Mattsson; J Rollof; J Verhoef; H Van Dijk; A Fleer
Journal:  Infect Immun       Date:  1994-09       Impact factor: 3.441

10.  Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease.

Authors:  Y Wang; S A Rollins; J A Madri; L A Matis
Journal:  Proc Natl Acad Sci U S A       Date:  1995-09-12       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.